India Globalization's Hyalolex Shows Promise in Treating Patients with Alzheimer's Disease -- CFN Media
08 févr. 2018 08h30 HE
|
CFN Media
Seattle, WA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum
04 janv. 2018 08h05 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate
23 nov. 2017 08h45 HE
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's...
Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference
08 nov. 2017 08h12 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th
30 oct. 2017 08h12 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812
16 oct. 2017 08h00 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, PA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting
23 août 2017 09h45 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate
19 juil. 2017 04h35 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 19, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the...
Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference
03 avr. 2017 08h00 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, April 03, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...